- Home
- TEAF vs SKYE Comparison
TEAF vs SKYE Comparison
Compare TEAF & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- SKYE
- Stock Information
- Founded
- TEAF 2017
- SKYE 2012
- Country
- TEAF United States
- SKYE United States
- Employees
- TEAF N/A
- SKYE N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- SKYE Health Care
- Exchange
- TEAF Nasdaq
- SKYE Nasdaq
- Market Cap
- TEAF 174.8M
- SKYE 94.0M
- IPO Year
- TEAF N/A
- SKYE N/A
- Fundamental
- Price
- TEAF $11.95
- SKYE $2.73
- Analyst Decision
- TEAF
- SKYE Buy
- Analyst Count
- TEAF 0
- SKYE 6
- Target Price
- TEAF N/A
- SKYE $18.67
- AVG Volume (30 Days)
- TEAF 56.1K
- SKYE 167.7K
- Earning Date
- TEAF 01-01-0001
- SKYE 02-09-2025
- Dividend Yield
- TEAF 9.20%
- SKYE N/A
- EPS Growth
- TEAF N/A
- SKYE N/A
- EPS
- TEAF N/A
- SKYE N/A
- Revenue
- TEAF N/A
- SKYE N/A
- Revenue This Year
- TEAF N/A
- SKYE N/A
- Revenue Next Year
- TEAF N/A
- SKYE N/A
- P/E Ratio
- TEAF N/A
- SKYE N/A
- Revenue Growth
- TEAF N/A
- SKYE N/A
- 52 Week Low
- TEAF $11.11
- SKYE $2.25
- 52 Week High
- TEAF $13.30
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- TEAF 35.01
- SKYE 37.40
- Support Level
- TEAF $11.84
- SKYE $2.31
- Resistance Level
- TEAF $12.21
- SKYE $3.04
- Average True Range (ATR)
- TEAF 0.13
- SKYE 0.30
- MACD
- TEAF 0.01
- SKYE 0.07
- Stochastic Oscillator
- TEAF 37.04
- SKYE 44.68
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.